By Fineline Cube Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system, LuX‑Valve Plus, was recently approved for commercialization by the Department of Health of the Hong Kong Special Administrative Region. The clearance marks the latest regulatory win for the world’s second approved transcatheter orthotopic tricuspid valve replacement product.
Regulatory Milestone
| Field | Detail |
|---|---|
| Agency | Department of Health, Hong Kong Special Administrative Region |
| Approval Type | Commercialization approval |
| Product | LuX‑Valve Plus transcatheter tricuspid valve replacement system |
| Indication | Tricuspid valve disease (orthotopic transcatheter tricuspid valve replacement) |
| Company | Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) |
| Date | 04 Sep 2026 |
| Next Steps | Continued clinical promotion and commercial expansion across approved markets |
Product Profile & Differentiation
- Device: LuX‑Valve Plus, a transcatheter orthotopic tricuspid valve replacement system.
- Global Standing: The world’s second approved transcatheter orthotopic tricuspid valve replacement product.
- Differentiation: The company cites differentiated product advantages as a key driver of market adoption.
- Clinical Foundation: Extensive clinical application experience accumulated to date supports ongoing commercialization.
- Market Recognition: Broad recognition gained through continuous clinical promotion efforts.
Commercial Footprint – Global Regulatory Approvals
| Region | Status |
|---|---|
| Greater China (incl. Hong Kong SAR) | Commercialization approval granted by the Department of Health of the Hong Kong SAR |
| Europe | Regulatory approvals obtained in multiple countries |
| Middle East | Regulatory approvals obtained |
| Asia‑Pacific | Regulatory approvals obtained in multiple countries and regions |
With the Hong Kong approval, LuX‑Valve Plus has now secured regulatory clearances across multiple countries and regions in Europe, the Middle East, and the Asia‑Pacific region — building a diversified international footprint for the transcatheter tricuspid valve replacement platform.
Market Impact & Outlook
- Category Position: As one of only two approved transcatheter orthotopic tricuspid valve replacement products worldwide, LuX‑Valve Plus holds first‑mover positioning in a rapidly emerging structural heart category.
- International Expansion: Approvals spanning Europe, the Middle East, and Asia‑Pacific broaden the addressable market and reduce single‑region dependence.
- Adoption Drivers: Differentiated design advantages, established clinical experience, and active clinical promotion underpin market recognition.
- Growth Trajectory: Continued regulatory and commercial momentum positions Jenscare to scale LuX‑Valve Plus adoption in underserved tricuspid valve disease populations.
Forward‑Looking Statements — This brief contains forward‑looking statements regarding Ningbo Jenscare Scientific Co., Ltd.‘s commercialization of LuX‑Valve Plus and its ongoing regulatory and market expansion for transcatheter tricuspid valve replacement. Such statements are based on current expectations and are subject to risks and uncertainties, including regulatory review, market acceptance, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.-Fineline Info & Tech